Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suratadenoturev - Oncolys Biopharma

Next Previous
Drug Profile

Suratadenoturev - Oncolys Biopharma

Alternative Names: OBP-301; Telomelysin; Telomerase-specific Type 5 Adenovirus OBP-301 - Oncolys Biopharma

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncolys Biopharma
  • Developer Chugai Pharmaceutical; Cornell University; Medigen Biotechnology Corporation; Okayama University; Oncolys BioPharma
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses; Viral proteins
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer
  • Phase I/II Liver cancer; Non-small cell lung cancer
  • No development reported Adenoid cystic carcinoma; Breast cancer; Mesothelioma; Neuroblastoma; Osteosarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Oesophageal-cancer(Combination therapy, Late-stage disease) in Japan (Intratumoural, Injection)
  • 10 Jan 2024 Adverse events data from a phase I trial in Oesophageal cancer and Gastric cancer released by NRG Oncology
  • 07 Nov 2023 Efficacy data from phase-II trial in Adenocarcinoma released by Oncolys BioPharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top